Role for positron emission tomography in skeletal diseases{lozenge, open}{lozenge, open}Pour citer cet article, utiliser ce titre en anglais et sa référence dans le même volume de Joint Bone Spine.;Tomographie par émission de positons. Quelle place en pathologie ostéoarticulaire ?

Revue du Rhumatisme (Edition Francaise)

Volumn 74, Issue 1, 2007, Pages 17-26

  Duet, Michèle ^a,c   Pouchot, Jacques ^a,c   Lioté, Frédéric ^b,c   Faraggi, Marc ^a,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Université de Médecine   (France)

Author keywords

18F FDG; Giant cell arteritis; Joint prosthesis infection; PET scan; Takayasu disease; Vasculitis

Indexed keywords

EID: 33846668401     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2006.04.012     Document Type: Short Survey

References (60)

1. Kubota K., Ishiwata K., Tamahashi N., and Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 33 (1992) 1972-1980
2. Schiepers C., Filmont J.M., and Czernin J. PET for staging of Hodgkin's disease and non- Hodgkin's lymphoma. Eur. J. Nucl. Med. 1 Suppl (2003) 82-88
3. Pakos E.E., Fotopoulos A.D., and Ionnidis J.P. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J. Nucl. Med. 46 (2005) 958-963
4. Yamane T., Daimaru O., Ito S., Yoshiya K., Nagata T., Ito S., et al. Decreased 18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas. J. Nucl. Med. 45 (2004) 1838-1842
5. 18F]FDG for therapy response monitoring in lymphoma patients. Eur. J. Nucl. Med. 1 Suppl (2003) 97-105
6. Reske S.N. PET and restaging of malignant lymphoma including residual masses and relapse. Eur. J. Nucl. Med. 30 suppl 1 (2003) S89-S96
7. Castellucci P., Zinzani P., Pourdehnad M., Alinari L., Nanni C., Farsad M., et al. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur. J. Nucl. Med. 32 (2005) 749-756
8. Weber W.A. Use of PET for monitoring cancer therapy and predicting outcome. J. Nucl. Med. 46 (2005) 983-995
9. Durie B.G.M., Waxman A.D., D'Agnolo A., and Williams C.M. Whole-body 18F-FDG PET identifies high-risk myeloma. J. Nucl. Med. 43 (2002) 1457-1463
10. Schirrmeister H., Bommer M., Buck A.K., Müller S., Bunjes D., Döhner H., et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur. J. Nucl. Med. 29 (2002) 361-366
11. Bredella M.A., Steinbach L., Caputo G., Seagull G., and Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR 184 (2005) 1199-1204
12. Folpe A.L., Lyles R.H., Sprouse J.T., Conrad III E.U., and Eary J.F. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin. Cancer Res. 6 (2000) 1279-1287
13. Shulte M., Brecht-Krauss D., Heymer B., Guhlmann A., Hartwig E., Sarkar M.R., et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J. Nucl. Med. 41 (2000) 1695-1701
14. Brenner W., Bohuslavizki K.H., and Eary J.F. PET imaging of osteosarcoma. J. Nucl. Med. 44 (2003) 930-942
15. Franzius C., Daldrup-Link H.E., Sciuk J., Rummeny E.J., Bielack S., Jurgens H., et al. FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann. Oncol. 12 (2001) 479-486
16. Franzius C., Sciuk J., Daldrup-Link H.E., Jürgens H., and Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. Eur. J. Nucl. Med. 27 (2000) 1305-1311
17. Daldrup-Link H., Franzius C., Link T.M., Laukamp D., Sciuk J., Jurgens H., et al. Whole-body MR imaging for detection of bone metastases in children and young adults. AJR 177 (2001) 229-236
18. Shulte M., Brecht-Krauss D., Werner M., Hartwig E., Sarkar M.R., Keppler P., et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J. Nucl. Med. 40 (1999) 1637-1643
19. Hawkins D.S., Rajendran J.G., Conrad III E.U., Bruckner J.D., and Eary J.F. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 94 (2002) 3277-3283
20. Franzius C., Daldrup-Link H.E., Wagner-Bohn A., Sciuk J., Heindel W.L., Jürgens H., et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann. Oncol. 13 (2002) 157-160
21. Blockmans D., Stroobants S., Maes A., and Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am. J. Med. 108 (2000) 246-249
22. Belhocine T., Blockmans D., Hustinx R., Vandevivere J., and Mortelmans L. Imaging of large vessel vasculitis with 18F-FDG PET: illusion or reality? A critical review of the literature data. Eur. J. Nucl. Med. Mol. Imaging 30 (2003) 1305-1313
23. Yun M., Yeh D., Araujo L.I., Jang S., Newberg A., and Alavi A. F-18 FDG uptake in the large arteries. A new observation. Clin. Nucl. Med. 26 (2001) 314-319
24. Moosig F., Czech N., Henze E., Zeuner R.A., Kneba M., and Schröder J.O. Correlation between 18F-FDG accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann. Rheum. Dis. 63 (2004) 870-873
25. Andrews J., Al-Nahhas A., Pennel D.J., Hossain M.S., Davies K.A., Haskard D.O., et al. Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann. Rheum. Dis. 63 (2004) 995-1000
26. Webb M., Chambers A., Al-Nahhas A., Mason J.C., Maudlin L., Rahman L., et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 627-634
27. 18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 674-681
28. Salvarani C., Pipitone N., Versari A., Vaglio A., Serafini D., Bajocchi G., et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum. 53 (2005) 298-303
29. Vaglio A., Versari A., Fraternali A., Ferrozzi F., Salvarani C., and Buzio C. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. Arthritis Rheum. 53 (2005) 122-125
30. Drieskens O., Blockmans D., Van den Bruel A., and Mortelmans L. Riedel's thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis. Positron emission tomographic findings. Clin. Nucl. Med. 27 (2002) 413-415
31. 18F]fluoro-D-glucose accumulation in a case of retroperitoneal fibrosis following resection of carcinoid tumor. Mol. Imag. Biol. 4 (2002) 363-368
32. Beckers C., Ribbens C., André B., Marcelis S., Kaye O., Mathy L., et al. Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET. J. Nucl. Med. 45 (2004) 956-964
33. Beckers C., Jeukens X., Ribbens C., Andre B., Marcelis S., Leclercq P., et al. (18)F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 275-280
34. 18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 48 (2003) 3077-3084
35. Gupta P., Ponzo F., and Kramer E.L. Fluorodeoxyglucose (FDG) uptake in pulmonary rheumatoid nodules. Clin. Rheumatol. 24 (2005) 402-405
36. Wendling D., Blagosklonov O., Streit G., Lehuede G., Toussirot E., and Cardot J.C. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment. Ann. Rheum. Dis. 64 (2005) 1663-1665
37. Zhuang H., Duarte P.S., Pourdehnad M., Maes A., Van Acker F., Shnier D., et al. The promising role of 18F-FDG-PET in detecting infected lower limb prosthesis implants. J. Nucl. Med. 42 (2001) 44-48
38. Schiesser M., Stumpe K.D.M., Trentz O., Kossmann T., and von Schulthess G.K. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results. Radiology 226 (2003) 391-398
39. Vanquickenborne B., Maes A., Nuyts J., Van Acker F., Stuyck J., Mulier M., et al. The value of 18F-FDG -PET for the detection of infected hip prosthesis. Eur. J. Nucl. Med. 30 (2003) 705-715
40. Zhuang H., Chacko T.K., Hickeson M., Stevenson K., Feng Q., Ponzo F., et al. Persistent non-specific FDG uptake on PET imaging following hip arthroplasty. Eur. J. Nucl. Med. 29 (2002) 1328-1333
41. 99mTc-HMPAO white blood cell SPECT and bone scintigraphy in the evaluation of painful total knee arthroplasties. Eur. J. Nucl. Med. 28 (2001) 1496-1504
42. Kälicke T., Schmitz A., Risse J.H., Arens S., Keller E., Hansis M., et al. Fluorine -18fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur. J. Nucl. Med. 27 (2000) 524-528
43. Gratz S., Dörner J., Fischer U., Behr T.M., Béhé M., Altenvoerde G., et al. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur. J. Nucl. Med. 29 (2002) 516-524
44. de Winter F., Gemmel F., van de Wiele C., Poffijn B., Uyttendaele D., and Dierckx R. 18-fluorine fluorodeoxyglucose positron emission tomography for the diagnosis of infection in the post-operative spine. Spine 28 (2003) 1314-1319
45. Stumpe K.D.M., Zanetti M., Weishaupt D., Hodler J., Boos N., and von Schulthess G.K. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR Imaging. AJR Am. J. Roentgenol. 179 (2002) 1151-1157
46. Kato K., Aoki J., and Endo K. Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phase. Ann. Nucl. Med. 17 (2003) 41-46
47. Shon I.H., and Fogelman I. F-18 FDG positron emission tomography and benign fractures. Clin. Nucl. Med. 28 (2003) 171-175
48. Zhuang H., Sam J.W., Chacko T.K., Duarte P.S., Hickeson M., Feng Q., et al. rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur. J. Nucl. Med. 30 (2003) 1096-1103
49. Schmitz A., Risse J.H., Textor J., Zander D., Biersack H.J., Schmitt O., et al. FDG-PET findings of vertebral compression fractures in osteoporosis: preliminary results. Osteoporos. Int. 13 (2002) 755-761
50. Brudin L.H., Valind S.O., Rhodes C.G., Pantin C.F., Sweatman M., Jones T., et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur. J. Nucl. Med. 21 (1994) 297-305
51. Lewis P.J., and Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J. Nucl. Med. 35 (1994) 1647-1649
52. El-Haddad G., Zhuang H., Gupta N., and Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin. Nucl. Med. 34 (2004) 313-329
53. Xiu Y., Yu J.Q., Cheng E., Kumar R., Alavi A., and Zhuang H. Sarcoidosis demonstrated by FDG PET imaging with negative findings on Gallium scintigrapy. Clin. Nucl. Med. 30 (2005) 193-195
54. Blockmans D., Knockaert D., Maes A., de Caestecker J., Stroobants S., Bobbaers H., et al. Clinical value of [18F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin. Infect. Dis. 32 (2001) 191-196
55. Meller J., Altenvoerde G., Munzel U., Jauho A., Behe M., Gratz S., et al. Fever of unknown origin: prospective comparison of [18]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur. J. Nucl. Med. 27 (2000) 1617-1625
56. Bleeker-Rovers C.P., de Kleijn E.M., Corstens F.H., Van der Meer J.W., and Oyen W.J. Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. Eur. J. Nucl. Med. Mol. Imaging 31 (2004) 29-37
57. Jan de Beur S.M., Streeten E.A., Civelek A.C., McCarthy E.F., Uribe L., Marx S.J., et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359 (2002) 761-763
58. Seufert J., Ebert K., Muller J., Eulert J., Hendrich C., Werner E., et al. Octreotide therapy for tumor-induced osteomalacia. N. Engl. J. Med. 345 (2001) 1883-1888
59. Dupond J.L., Mahammedi H., Prié D., Collin F., Gil H., Blagosklonov O., et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT SCAN for the diagnosis and follow-up in one case. Bone 36 (2005) 375-378
60. Bhargava P., Naydich M., and Ghesani M. Normal F-18 FDG verbebral uptake in Paget's disease on PET scanning. Clin. Nucl. Med. 30 (2005) 191-192